A group of FDA advisers unanimously voted to recommend approval for prasugrel, an anti-clotting medicine from Eli Lilly and Co. and Daiichi Sankyo. The panel also said prasugrel's label should warn physicians against its use in people who have suffered a stroke or are possible candidates for open-heart surgery.

Full Story:
Google, NYTimes.com

Related Summaries